MedTrace Logo

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

NCT02294305 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-08-24

No results posted yet for this study

Summary

This placebo-controlled study is designed to determine the efficacy, safety, and tolerability of vortioxetine in the treatment of adults with Major Depressive Disorder (MDD) that is comorbid with Social Anxiety Disorder (SAD). Half of the subjects will be randomized to receive vortioxetine and the other half will receive placebo.

Conditions

Interventions

DRUG

Vortioxetine

DRUG

Placebo

Sponsors & Collaborators

  • The Medical Research Network

    lead OTHER

Principal Investigators

  • Michael R Liebowitz, M.D. · The Medical Research Network, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02294305 on ClinicalTrials.gov